Recently, researchers have been experimenting with a novel, automated, high-precision, kinematic movement analysis system that can be utilized to detect subtle phenotype changes, with earlier and more sensitive detection compared to traditional movement analysis. The system provides a more comprehensive study of fine motor performance and motor deficits than previous methods, which is necessary to fully model the aspects of human CNS disease in preclinical models.
Monoclonal antibodies (mAbs) are among the fastest-growing products in the field of biologics. Choosing the most appropriate in vitro test for routine testing throughout the life cycle of the mAb requires an intimate knowledge of how well the drug works in vivo.
Craig B. Thompson, CEO of Memorial Sloan-Kettering Cancer Center, was appointed to the board of directors to help Charles River grow through identifying promising new technologies the company could license or acquire and by strengthening its ties to the academic community.
Emily Hickey, Corporate Vice President, Discovery Research Services, talked to SelectScience about the companies’ recently released therapeutic models, lead generation and the global evolution of the model for drug discovery.
GEN recently spoke to a number of cell-line authentication experts to find out just how large a problem cell-line misidentification is and to determine what companies are doing to address this issue.
Companies large and small have been strategically using CROs for targeted segments of their discovery work in order to maximize the effectiveness and impact of their own internal resources. By generating robust, translatable data with state-of-the-art methods, a CRO can offer the kind of unbiased, objective assessment that aids the decision of whether to move a leading candidate forward or shelve it and continue searching for a better one.
Despite ongoing slowness in the market for early-stage research, preclinical specialist Charles River Laboratories boosted its revenue and income in the third quarter, a credit to its continued cost cuts and gains in market share.
The right CRO, with expertise and experience in drug discovery and development, can be a great asset in consulting and helping to design and execute project plans and studies from the very beginning. A good CRO partner can offer the flexibility and know-how so that you have the right science at the right time.
Charles River will introduce four pain models (rat) for translational disease research this fall.
Theorem Clinical Research and Charles River Laboratories have formed an alliance that will provide nonclinical testing programs in the areas of bioanalysis, immunogenicity and immunology to support trials.